FDA unit launches workshops to encourage orphan-drug applications

03/9/2010 | Wall Street Journal, The

The FDA's Office of Orphan Products Development is hosting workshops to encourage research into treatments for rare diseases among drug and biotech companies, academic institutes as well as patient advocates. The first seminar was held last month and resulted in 14 submissions for orphan-drug status out of 29 potential sponsors, but Timothy Coté, director of the division, said he hopes to gather more applications during the second workshop in August.

View Full Article in:

Wall Street Journal, The